(MENAFN- Straits Research)
Market Overview
The India Cardiac Resynchronization Therapy (CRT) Market size was valued at USD 306 million in 2025 and is projected to grow from USD 336.97 million in 2026 to reach USD 728.65 million by 2034, growing at a CAGR of 10.12% during the forecast period 2026–2034.
Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.
The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.
Highlights
CRT-D dominates the market by Product.
Hospitals dominate the market by End-User.
Download a Free Sample To learn more about this report,
Market Dynamics
India Cardiac Resynchronization Therapy (crt) Market Drivers
High Prevalence of Cardiac Diseases
Heart failure and arrhythmias are two of the major cardiovascular illnesses in India. There is a demand for effective treatment alternatives like CRT because of the increasing prevalence of these illnesses, which is linked to factors including sedentary behavior, lifestyle changes, and rising obesity rates. The demand for cutting-edge cardiac therapy drives the adoption of CRT devices in the Indian market.
Increasing Aging Population
With a growing older population, India is experiencing a demographic transition. Heart failure and other cardiac problems are more likely to develop in older adults. As seniors are more likely to need cardiac resynchronization therapy, India's aging population expands the patient pool for CRT devices. The aging population is a major factor in the expansion of the CRT market.
India Cardiac Resynchronization Therapy (crt) Market Restraints
high Cost of Device
The demand for CRT devices is anticipated to be constrained by their high cost, particularly in developing and undeveloped economies. These gadgets are priced differently depending on the brand. Devices that are MRI-compatible cost more than those that are not.
Further restricting the market is that governments in many developing nations, including India, do not offer price caps on these gadgets. In India, a CRT-D implant costs roughly USD 16,500 on average. Depending on the facility and surgeon, this cost can range from USD 7,000 to USD 25,000.
This price is greater than the price range of USD 650 to USD 2,600 for automatic external defibrillators. In a similar vein, pacemakers cost between USD 3,000 and USD 4,000.
Therefore, the high price of CRT is expected to have a detrimental effect on the market.
India Cardiac Resynchronization Therapy (crt) Market Opportunities
Government Initiatives
The Indian government has invested in constructing hospitals, clinics, and cardiac care facilities. These programs seek to increase accessibility to high-quality healthcare services, including cutting-edge cardiac therapies like CRT. Expanding the healthcare infrastructure makes the adoption of CRT equipment and processes possible.
The Indian government is key in encouraging patient access to CRT through its health insurance programs and payment rules. Public health insurance programs for qualifying patients, including Ayushman Bharat and state-specific health insurance plans, cover particular cardiac operations and equipment, including CRT. These reimbursement procedures promote CRT use and lower patient costs, resulting in market expansion.
India Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis
By Product
The India Cardiac Resynchronization Therapy (CRT) Market is segmented into CRT-Defibrillator and CRT-Pacemaker. CRT-Defibrillators combine cardiac resynchronization capabilities with implantable cardioverter-defibrillator functionality, helping improve ventricular synchronization while providing protection against potentially life-threatening ventricular arrhythmias. CRT-Pacemakers are primarily designed to coordinate ventricular contractions and improve cardiac function in eligible patients with heart failure and conduction abnormalities. CRT-Defibrillators represent the leading product segment in India, supported by their combined resynchronization and defibrillation capabilities and increasing demand for advanced cardiac rhythm management solutions.
Increasing prevalence of cardiovascular diseases, growing incidence of heart failure and arrhythmias, rising awareness of advanced cardiac therapies, and improvements in healthcare infrastructure are supporting demand across both product categories. CRT-Pacemakers are also gaining importance as diagnosis and management of heart failure and conduction disorders improve across the country. Technological advancements in device design, battery performance, lead technology, remote monitoring, and intelligent pacing are expected to strengthen adoption of CRT systems, while increasing disposable incomes and expanding access to specialized cardiac care are supporting market development in India.
Request Customization to receive a tailored report.
By End User
The India Cardiac Resynchronization Therapy (CRT) Market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other End Users. Hospitals represent the leading end-user segment because CRT implantation requires specialized cardiovascular infrastructure, diagnostic capabilities, trained cardiac specialists, and post-procedure monitoring. Cardiac centers provide specialized services for cardiovascular diagnosis, device implantation, rhythm management, and patient follow-up, while ambulatory surgical centers are increasingly relevant for selected procedures that can be performed in outpatient settings. Other end users include specialized healthcare facilities and medical institutions involved in cardiac rhythm management and cardiovascular care.
Growing demand for advanced cardiac treatment, increasing prevalence of heart failure and cardiac rhythm disorders, expansion of specialized cardiac facilities, and improving access to cardiovascular services are supporting demand across end-user settings. Hospitals continue to benefit from their comprehensive cardiac-care infrastructure, while cardiac centers are gaining importance because of their specialized expertise and increasing focus on advanced rhythm-management procedures. Ambulatory surgical centers can benefit from the expansion of outpatient cardiac interventions, while remote monitoring and improved follow-up technologies are supporting long-term management of CRT patients. Rising healthcare expenditure, increasing cardiac health awareness, and continued expansion of healthcare infrastructure are expected to support CRT adoption across India.
Speak to an Analyst to discuss market opportunities.
Regional Analysis of the Cardiac Resynchronization Therapy (CRT) Market
According to a study that was published in the Indian Heart Journal in December 2018, only 116 out of 471 heart failure patients (24.6%) chose to have a CRT device implanted because of economic reasons. After two years, it was discovered that patients who received CRT had better clinical outcomes. Over the forecast period, rising disposable income, expanding healthcare infrastructure, and rising cardiac health awareness are expected to drive the market. International competitors are also growing their operations to take market share in the nation. Abbott supported its growth goals by introducing a new portfolio of CRT-Ds and ICDs in India in October 2020.
List of Key and Emerging Players in India Cardiac Resynchronization Therapy (CRT) Market
Abbott
Boston Scientific Corporation
Medtronic
Biotronik SE & Co. Kg
Microport Scientific Corporation
LivaNova PLC
Medico S.R.L.
Key Industry Developments
June 2026: Medtronic expanded its cardiac rhythm management portfolio in India by advancing next-generation Cardiac Resynchronization Therapy (CRT) devices featuring enhanced remote monitoring, longer battery life, and AI-enabled diagnostics. The company focused on improving outcomes for patients with heart failure.
May 2026: Abbott expanded its electrophysiology and cardiac rhythm management portfolio by introducing advanced CRT-P and CRT-D systems with improved lead technology and integrated remote patient monitoring capabilities for healthcare providers across India.
April 2026: Boston Scientific expanded its cardiac rhythm management solutions by advancing MRI-compatible CRT devices with enhanced arrhythmia detection, adaptive pacing technologies, and digital patient management features.
January 2026: BIOTRONIK expanded its cardiac rhythm management portfolio in India by introducing advanced CRT systems with remote monitoring capabilities and intelligent pacing algorithms designed to improve heart failure management.
Report Scope
Comments
No comment